OptiNose (OPTN) Tops Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to OptiNose (OPTN) Tops Q3 EPS by 1c

Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

November 10, 2022 7:00 AM EST

Company plans to submit an sNDA for XHANCE as a treatment for chronic sinusitis in early 2023

Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCEs Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients

Company reports third quarter 2022 XHANCE net revenue of $20.1 million

Company expects full year 2022 XHANCE net revenue to be between $74 to $78 million

Company expects full year 2022 operating expenses to be between $127 to $131 million; full year 2023 operating expenses... More